Detected ·
Attovia Therapeutics
$289M—
Attovia Therapeutics raised $289M in an upsized IPO on Nasdaq (ticker: $ATTO), climbing 29% after its debut. The biotech focuses on next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY™ biparatopic VHH-based platform.
- Website
- www.attovia.com
- Amount
- $289 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-06 00:04:06 UTC
- Signal ID
- 5920d8f5-df9f-4933-86be-981cada20608
As the API returns it
{
"id": "5920d8f5-df9f-4933-86be-981cada20608",
"created_at": "2026-08-06T00:04:06.585645Z",
"company_name": "Attovia Therapeutics",
"company_website_url": "www.attovia.com",
"company_linkedin_url": "https://www.linkedin.com/company/attovia-therapeutics",
"event_type": "funding",
"funding_amount": 289000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Attovia Therapeutics raised $289M in an upsized IPO on Nasdaq (ticker: $ATTO), climbing 29% after its debut. The biotech focuses on next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY™ biparatopic VHH-based platform.*"
}